ArticleAmerican heart journal2015
Copeptin is an independent predictor of diabetic heart disease and death.
Article in American heart journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Copeptin as biomarker for acute ischemic stroke prognosis and revascularization treatment efficacy.Frontiers in neurology · 2024Pooled it
- Acute kidney injury biomarker responses in young and older female adults following mild hypohydration.American journal of physiology. Renal physiology · 2026Trial
- Water Supplementation Reduces Copeptin and Plasma Glucose in Adults With High Copeptin: The H2O Metabolism Pilot Study.The Journal of clinical endocrinology and metabolism · 2019Trial
- Effect of intentional daily liter of plain water on total fluid and caloric intake among free-living adults.PloS one · 2026Article
- Body mass index and the risk of ulnar nerve entrapment in individuals without diabetes-a longitudinal cohort study from Sweden.International journal of obesity (2005) · 2025Article
- Association of serum osmolality with metabolic dysfunction-associated steatotic liver disease in adults.BMC gastroenterology · 2025Article
- Copeptin as a New Blood-Based Marker for Differential Diagnosis in Stroke Patients.International journal of molecular sciences · 2025Review
- Long-term health outcomes associated with hydration status.Nature reviews. Nephrology · 2024Review
- The association between water intake and future cardiometabolic disease outcomes in the Malmö Diet and Cancer cardiovascular cohort.PloS one · 2024Article
- The association of copeptin with metabolic risk markers is modified by region of origin.Scientific reports · 2023Article
- The Importance of Optimal Hydration in Patients with Heart Failure-Not Always Too Much Fluid.Biomedicines · 2023Review
- Short-term association between outdoor temperature and the hydration-marker copeptin: a pooled analysis in five cohorts.EBioMedicine · 2023Article
- Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment.Life (Basel, Switzerland) · 2023Review
- Ageing restructures the transcriptome of the hypothalamic supraoptic nucleus and alters the response to dehydration.npj aging · 2023Article
- Emerging Biomarkers for Predicting Clinical Outcomes in Patients with Heart Disease.Life (Basel, Switzerland) · 2023Review
- Personalized prediction of optimal water intake in adult population by blended use of machine learning and clinical data.Scientific reports · 2022Article
- Admission of patients with chest pain and/or breathlessness from the emergency department in relation to risk assessment and copeptin levels - an observational study.Upsala journal of medical sciences · 2022Observational
- Daily Fluid Intake Behaviors and Associated Health Effects Among Australian and United States Populations.Frontiers in sports and active living · 2022Article
- Copeptin as a marker of atherosclerosis and arteriosclerosis.Atherosclerosis · 2021Article
- The Road to Healthy Ageing: What Has Indonesia Achieved So Far?Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundWe previously discovered that high copeptin is associated with incidence of diabetes mellitus (diabetes), abdominal obesity, and albuminuria. Furthermore, copeptin predicts cardiovascular events after myocardial infarction in diabetic patients, but whether it is associated with heart disease and death in individuals without diabetes and prevalent cardiovascular disease is unknown. In this study, we aim to test whether plasma copeptin (copeptin), the C-terminal fragment of arginine vasopressin prohormone, predicts heart disease and death differentially in diabetic and nondiabetic individuals.
methodsWe related plasma copeptin to a combined end point composed of coronary artery disease (CAD), heart failure (HF), and death in diabetes (n = 895) and nondiabetes (n = 4187) individuals of the Malmö Diet and Cancer Study-Cardiovascular cohort.
resultsCopeptin significantly interacted with diabetes regarding the combined end point (P = .006). In diabetic individuals, copeptin predicted the combined end point (hazard ratio [HR] 1.32 per SD, 95% CI 1.10-1.58, P = .003) after adjustment for conventional risk factors, prevalent HF and CAD, and remained significant after additional adjustment for either fasting glucose (P = .02) or hemoglobin A1c (P = .02). Furthermore, in diabetic individuals, copeptin predicted CAD (HR 1.33 per SD, 95% CI 1.04-1.69, P = .02), HF (HR 1.62 per SD, 95% CI 1.09-2.41, P = .02), and death (HR 1.32 per SD, 95% CI 1.04-1.68, P = .02). Interestingly, among nondiabetic individuals, copeptin was not associated with any of the end points.
conclusionsCopeptin predicted heart disease and death, specifically in diabetes patients, suggesting copeptin and the vasopressin system as a prognostic marker and therapeutic target for diabetic heart disease and death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.